Omega Therapeutics Management
Management criteria checks 0/4
We currently do not have sufficient information about the CEO.
Key information
Kaan Certel
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | less than a year |
| Board average tenure | 1.3yrs |
Recent management updates
Recent updates
Omega Therapeutics And Novo Nordisk Collaboration: A Cautious 'Buy'
Mar 31Is Omega Therapeutics (NASDAQ:OMGA) Weighed On By Its Debt Load?
Feb 28
Omega Therapeutics: The Next Weight Loss Drug Runner
Jan 16Omega Therapeutics: Starting 2024 With A Bang
Jan 10Omega Therapeutics GAAP EPS of -$0.54 in-line, revenue of $0.48M beats by $0.43M
Aug 04Omega Therapeutics gets FDA nod to start liver cancer trial of lead drug OTX-2002
Jul 14CEO
Kaan Certel
less than a year
Tenure
Dr. Kaan Certel, Ph D., serves as President, CEO & Director at Omega Therapeutics, Inc. since November 2024 and was its Chief Business Officer since May 2024 until November 2024. Dr. Certel is a recognized...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | less than a year | no data | no data | |
| Founder | 7.9yrs | US$20.33k | no data | |
| Principal Financial Office | less than a year | no data | 0.068% $ 31.4k | |
| Chief Scientific Officer | less than a year | no data | no data | |
| Senior Vice President of Investor Relations & Corporate Affairs | less than a year | no data | no data | |
| Chief People Officer | 1.9yrs | no data | no data | |
| VP and Head of Computational Genomics & Data Sciences | 3.3yrs | no data | no data | |
| Senior Vice President of Clinical Development Operations | less than a year | no data | no data | |
| Senior Vice President of Early Discovery | less than a year | no data | no data |
0.9yrs
Average Tenure
Experienced Management: OMGA's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | less than a year | no data | no data | |
| Independent Chairman of Board | 1.4yrs | US$135.55k | 0% $ 0 | |
| Founding Scientific Advisor | no data | US$265.18k | 1.33% $ 615.1k | |
| Independent Director | 5.5yrs | US$153.68k | 0% $ 0 | |
| Independent Director | 2.3yrs | US$148.68k | 0% $ 0 | |
| Scientific Advisor | no data | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | 3.8yrs | US$149.19k | 0% $ 0 | |
| Director | less than a year | no data | no data | |
| Director | no data | no data | no data | |
| Independent Director | 1.3yrs | US$97.51k | 0% $ 0 |
1.3yrs
Average Tenure
65yo
Average Age
Experienced Board: OMGA's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 01:10 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Omega Therapeutics, Inc. is covered by 8 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ryan Deschner | CGS International |
| Keay Nakae | Chardan Capital Markets, LLC |
| Robert Burns | H.C. Wainwright & Co. |